RecruitingNot Applicable

Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

Australia30 participantsStarted 2025-07-07

Plain-language summary

The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Liver
✓. Adrenal
✓. Abdomino-pelvic lymph node
✓. Other abdominal site e.g. pancreatic, renal.
✓. Other pelvic site
✓. Bony or lung is allowed only if in conjunction with an abdominal site above

What they're measuring

Rate of local control (Local Response Rate).

Timeframe: Clinical progress imaging every 3 months post radiotherapy treatment until 3 years post radiotherapy.

Trial details

NCT IDNCT06604533

SponsorAustralasian Gastro-Intestinal Trials Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2030-01

Contact for this trial

Sukanya Sathyamurthie

+61 2 7208 2719 sukanya@gicancer.org.au

View on ClinicalTrials.gov More Abdominal Cancer trials